CRISPR Therapeutics Sees Commercial Ramp Driving Valuation
Seeking Alpha published April 1, 2026, rates CRISPR Therapeutics (CRSP) Buy with a 12-month price target of $64.58, citing CASGEVY's commercial ramp and rising patient initiations. The note highlights CRSP's in vivo cardiovascular pipeline — CTX310 and CTX320/321 — targeting large underserved markets, and roughly $2.5 billion cash supporting disciplined capital management. Analyst frames CASGEVY revenue as a near-term path to profitability.
Key Points
- 1Rates Buy and sets $64.58 12-month price target, citing CASGEVY commercial ramp.
- 2Highlights in vivo cardiovascular programs CTX310/320/321 targeting large underserved markets.
- 3Notes ~$2.5 billion cash and CASGEVY revenue progression enabling path to profitability.
Scoring Rationale
Fresh investment note provides directly usable guidance (price target, buy rating) and cites meaningful cash and pipeline metrics, raising actionability. Score lowered by single-source analyst opinion, limited novelty, and narrow company focus rather than industry-wide impact.
Sources
Public references used for this report.
Practice with real Telecom & ISP data
90 SQL & Python problems · 15 industry datasets
250 free problems · No credit card
See all Telecom & ISP problems